Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$24.00
-1.00 (-4.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-696.5M · quality 66.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-54.1%
↓Gross Margin
48.3%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-26.8%
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue $429.0M · net income $-876.0M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $429.0M | $429.0M | $316.0M | $617.0M | $1.09B |
| Net Income | $-876.0M | $-876.0M | $-1.94B | $-1.11B | $-2.55B |
| EBITDA | $-862.0M | $-862.0M | $-1.76B | $-635.0M | $-1.94B |
| EPS | — | — | -9.77 | -6.62 | -16.77 |
| Gross Margin | 48.3% | 48.3% | 58.5% | 54.6% | 60.6% |
| Operating Margin | -200.5% | -200.5% | -617.1% | -184.6% | -226.3% |
| Net Margin | -204.2% | -204.2% | -614.2% | -180.2% | -233.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.03 | 0.01 |
| Current Ratio | 8.02 | 8.02 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | — | — | $-1.03B | $-359.0M | $-2.48B |
| Returns | |||||
| ROE | -54.1% | -54.1% | -187.5% | -59.3% | -95.7% |
| Valuation | |||||
| P/B | 3.90 | 3.90 | 6.91 | 4.04 | 2.68 |
| Growth & Yield | |||||
| Revenue Growth | 35.8% | 35.8% | -48.8% | -43.5% | — |
| EPS Growth | — | — | -47.6% | 60.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-22.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-9.77 → n/d
Residual
-22.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.